Home > Insider Trading > Filing (0001213900-24-074051)

Filing Details

Accession Number:: 0001213900-24-074051
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-08-29 19:36:55
Reporting Period:: 2024-08-27

Accepted Time:: 2024-08-29 19:36:55
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1484565	Soleno Therapeutics Inc	SLNO	Electromedical & Electrotherapeutic Apparatus (3845)	770523891

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1728970	Vivo Opportunity, Llc	192 Lytton Avenue Palo Alto, CA 94301		No	No	Yes	No
1930214	Vivo Opportunity Fund Holdings, L.p.	192 Lytton Avenue Palo Alto, CA 94301		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2024-08-27	500,000	$48.73	6,816,851	No	4	S	Indirect	By Vivo Opportunity Fund Holdings, L.P.
Common Stock	Disposition	2024-08-28	425,000	$47.35	6,391,851	No	4	S	Indirect	By Vivo Opportunity Fund Holdings, L.P.
Common Stock	Disposition	2024-08-29	100,000	$47.22	6,291,851	No	4	S	Indirect	By Vivo Opportunity Fund Holdings, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Vivo Opportunity Fund Holdings, L.P.
No	4	S	Indirect	By Vivo Opportunity Fund Holdings, L.P.
No	4	S	Indirect	By Vivo Opportunity Fund Holdings, L.P.

Footnotes

Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $47.00 to $51.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (2) to this Form 4.
The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $46.79 to $48.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4.
The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $46.47 to $47.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4.